Cellestia Biotech is focused on developing innovative therapeutics that target previously undruggable pathways in autoimmune diseases and multi-drug resistant cancers. Their lead product, CB-103, is a first-in-class therapy that inhibits specific nuclear transcription factors involved in cellular signaling related to these diseases. The company has demonstrated the safety and efficacy of CB-103 through successful Phase 1 clinical trials, which showed strong target engagement and downregulation of key genes. This positions Cellestia to advance into Phase 2 trials, targeting genetically defined orphan cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and adenoid cystic carcinoma (ACC), as well as addressing graft-versus-host disease (GvHD) in stem cell transplant patients.

In addition to CB-103, Cellestia has a robust pipeline of pre-clinical assets that have shown promise in treating a variety of conditions, including virus-induced cancers and chronic autoimmune disorders. Their innovative approach combines structural biology, structure-activity relationships, and machine learning to develop small molecule inhibitors that can modulate T regulatory cells and T effector cells in vivo. This unique capability not only aims to provide effective treatments for cancer but also holds potential for addressing significant unmet medical needs in autoimmune and inflammatory diseases, thereby improving the quality of life for patients with limited treatment options.

Switzerland

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)

Cellestia Biotech

Company Details